share_log

藥明康德：根據2019年A股激勵計劃特別授予的限制性A股股票解除限售及上市流通

WUXI APPTEC: UNLOCKING AND TRADING OF THE RESTRICTED A SHARES GRANTED UNDER THE SPECIAL GRANT OF THE 2019 A SHARE INCENTIVE PLAN

香港交易所 ·  Mar 1 07:05
Summary by Moomoo AI
药明康德宣布，根據2019年A股激勵計劃，特別授予的限制性A股股票已達成解除限售條件，將於2024年3月7日開始上市流通。該激勵計劃於2019年通過，並於同年11月25日首次授予限制性A股股票。經過連續幾年的解除限售期，第四批限制性A股股票將在2024年3月1日進入最後一個解除限售期，佔激勵對象所獲授股份的40%。本次解除限售的股票數量為83,629股，經過2019年及2020年利潤分配方案調整後的數量。药明康德的中國法律顧問方達律師事務所確認，解除限售符合相關法律及激勵計劃的規定。
药明康德宣布，根據2019年A股激勵計劃，特別授予的限制性A股股票已達成解除限售條件，將於2024年3月7日開始上市流通。該激勵計劃於2019年通過，並於同年11月25日首次授予限制性A股股票。經過連續幾年的解除限售期，第四批限制性A股股票將在2024年3月1日進入最後一個解除限售期，佔激勵對象所獲授股份的40%。本次解除限售的股票數量為83,629股，經過2019年及2020年利潤分配方案調整後的數量。药明康德的中國法律顧問方達律師事務所確認，解除限售符合相關法律及激勵計劃的規定。
KAND Pharmaceuticals announced that under the 2019 A Share Incentive Scheme, the special restricted A shares have been lifted and will commence public circulation on March 7, 2024. The incentive program was approved in 2019 and granted limited A shares for the first time on November 25 of the same year. After several consecutive years of delisting, the fourth batch of Restricted A Shares will enter the final delisting period on March 1, 2024, representing 40% of the shares granted to the Incentive. The number of shares outstanding for this delisting is 83,629 shares, after adjusting the 2019 and 2020 profit distribution plans. Fanta Law Firm, China Legal Advisors of Pharmaceutical Ming Kand, confirmed that the removal of the sales restriction complies with the relevant laws and incentive schemes.
KAND Pharmaceuticals announced that under the 2019 A Share Incentive Scheme, the special restricted A shares have been lifted and will commence public circulation on March 7, 2024. The incentive program was approved in 2019 and granted limited A shares for the first time on November 25 of the same year. After several consecutive years of delisting, the fourth batch of Restricted A Shares will enter the final delisting period on March 1, 2024, representing 40% of the shares granted to the Incentive. The number of shares outstanding for this delisting is 83,629 shares, after adjusting the 2019 and 2020 profit distribution plans. Fanta Law Firm, China Legal Advisors of Pharmaceutical Ming Kand, confirmed that the removal of the sales restriction complies with the relevant laws and incentive schemes.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more